{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T04:02:42Z","timestamp":1788321762051,"version":"build-2803163510"},"reference-count":33,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy Research"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.eplepsyres.2014.04.014","type":"journal-article","created":{"date-parts":[[2014,5,14]],"date-time":"2014-05-14T04:49:39Z","timestamp":1400042979000},"page":"1243-1252","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":62,"title":["Long-term safety and efficacy of eslicarbazepine acetate in patients with focal seizures: Results of the 1-year ESLIBASE retrospective study"],"prefix":"10.1016","volume":"108","author":[{"given":"V.","family":"Villanueva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"Serratosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Guillam\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Garc\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.G.","family":"Gir\u00e1ldez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Toledo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Salas-Puig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.J.","family":"L\u00f3pez Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Flores","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Rodr\u00edguez-Uranga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Castillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.A.","family":"Mauri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.L.","family":"Camacho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"L\u00f3pez-Gom\u00e1riz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Giner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Palau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Molins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eplepsyres.2014.04.014_bib0005","series-title":"67th Annual Meeting of the American Epilepsy Society","first-page":"128","article-title":"Eslicarbazepine acetate as adjunctive therapy in patients with refractory partial-onset seizures: safety results of a 12-week randomized placebo-controlled study [poster]","author":"Abou-Khalil","year":"2013"},{"key":"10.1016\/j.eplepsyres.2014.04.014_bib0010","series-title":"The Treatment of Epilepsy","first-page":"485","article-title":"Eslicarbazepine acetate","author":"Almeida","year":"2009"},{"key":"10.1016\/j.eplepsyres.2014.04.014_bib0015","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1684\/epd.2010.0303","article-title":"The evolution of antiepileptic drug development and regulation","volume":"12","author":"Arzimanoglou","year":"2010","journal-title":"Epileptic Disord."},{"key":"10.1016\/j.eplepsyres.2014.04.014_bib0020","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1528-1157.1981.tb06159.x","article-title":"Commission on classification and terminology of the international league against epilepsy. Proposal for revised clinical and electroencephalographic classification of epileptic seizures","volume":"22","author":"Bancaud","year":"1981","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2014.04.014_bib0025","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/j.1528-1167.2010.02522.x","article-title":"Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005\u20132009","volume":"51","author":"Berg","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2014.04.014_bib0030","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.eplepsyres.2012.02.005","article-title":"Satisfaction with antiepileptic drugs in children and adolescents with newly diagnosed and chronic epilepsy","volume":"100","author":"Beghi","year":"2012","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2014.04.014_bib0035","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1021\/jm980627g","article-title":"Anticonvulsant and sodium channel-blocking properties of novel 10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide derivatives","volume":"42","author":"Benes","year":"1999","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.eplepsyres.2014.04.014_bib0040","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.eplepsyres.2010.01.014","article-title":"Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy","volume":"89","author":"Ben-Menachem","year":"2010","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2014.04.014_bib0045","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/j.1528-1167.2008.01946.x","article-title":"Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study","volume":"50","author":"Elger","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2014.04.014_bib0050","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.yebeh.2012.08.027","article-title":"Adherence to antiepilepsy drug therapy","volume":"25","author":"Faught","year":"2012","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2014.04.014_bib0055","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/j.1528-1167.2008.01794.x","article-title":"Impact of nonadherence to antiepileptic drugs on health care utilization and costs: findings from the RANSOM study","volume":"50","author":"Faught","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2014.04.014_bib0060","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1212\/01.WNL.0000123695.22623.32","volume":"62","author":"French","year":"2004","journal-title":"Neurology"},{"issue":"Suppl. 1","key":"10.1016\/j.eplepsyres.2014.04.014_bib0065","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1528-1167.2007.00992.x","article-title":"Refractory epilepsy: clinical overview","volume":"48","author":"French","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2014.04.014_bib0070","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/j.1528-1167.2012.03605.x","article-title":"Efficacy and safety of eslicarbazepine acetate as add-on treatment in patients with focal-onset seizures: integrated analysis of pooled data from double-blind phase III clinical studies","volume":"54","author":"Gil-Nagel","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2014.04.014_bib0075","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1600-0404.2009.01218.x","article-title":"Efficacy and safety of 800 and 1200mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures","volume":"120","author":"Gil-Nagel","year":"2009","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.eplepsyres.2014.04.014_bib0080","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1111\/j.1528-1167.2010.02660.x","article-title":"Long-term efficacy and safety of eslicarbazepine acetate: results of a 1-year open-label extension study in partial-onset seizures in adults with epilepsy","volume":"51","author":"Halasz","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2014.04.014_bib0085","first-page":"257","article-title":"Inhibitory effects of eslicarbazepine acetate and its metabolites against neuronal voltage-gated sodium channels","volume":"52","author":"Hebeisen","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2014.04.014_bib0090","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1212\/WNL.0b013e318204a36a","article-title":"Estimating risk for developing epilepsy: a population-based study in Rochester, Minnesota","volume":"76","author":"Hesdorffer","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2014.04.014_bib0095","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.eplepsyres.2012.07.014","article-title":"Long-term safety and efficacy of eslicarbazepine acetate as adjunctive therapy in the treatment of partial-onset seizures in adults with epilepsy: results of a 1-year open-label extension study","volume":"103","author":"Hufnagel","year":"2013","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2014.04.014_bib0100","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.eplepsyres.2005.05.005","article-title":"Effectiveness of lamotrigine in clinical practice: results of a retrospective population-based study","volume":"65","author":"Knoester","year":"2005","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2014.04.014_bib0105","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1056\/NEJMra1004418","article-title":"Drug-resistant epilepsy","volume":"365","author":"Kwan","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.eplepsyres.2014.04.014_bib0110","article-title":"Post-authorisation study of eslicarbazepine as treatment for drug-resistant epilepsy: preliminary results","author":"Massot","year":"2013","journal-title":"Neurologia"},{"key":"10.1016\/j.eplepsyres.2014.04.014_bib0115","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1056\/NEJM199209103271104","article-title":"A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. The Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group","volume":"327","author":"Mattson","year":"1992","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.eplepsyres.2014.04.014_bib0120","doi-asserted-by":"crossref","first-page":"309","DOI":"10.33588\/rn.5606.2013031","article-title":"Eslicarbazepine acetate in clinical practice. Efficacy and safety results","volume":"56","author":"Serrano-Castro","year":"2013","journal-title":"Rev. Neurol."},{"key":"10.1016\/j.eplepsyres.2014.04.014_bib0125","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1053\/seiz.2000.0391","article-title":"Oxcarbazepine: a review","volume":"9","author":"Shorvon","year":"2000","journal-title":"Seizure"},{"key":"10.1016\/j.eplepsyres.2014.04.014_bib0130","first-page":"54","article-title":"Slow and fast inactivation of voltage-gated sodium channels by eslicarbazepine and carbamazepine","volume":"53","author":"Soares-da-Silva","year":"2012","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2014.04.014_bib0135","series-title":"67th Annual Meeting of the American Epilepsy Society","first-page":"210","article-title":"Adjunctive eslicarbazepine acetate in patients with refractory partial-onset seizures: efficacy results of a 12 week randomized placebo-controlled study [poster]","author":"Sperling","year":"2013"},{"key":"10.1016\/j.eplepsyres.2014.04.014_bib0140","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1007\/s00115-010-3177-3","article-title":"Abrupt switch from extended-release oxcarbazepine to eslicarbazepine acetate","volume":"82","author":"Steinhoff","year":"2011","journal-title":"Nervenarzt"},{"key":"10.1016\/j.eplepsyres.2014.04.014_bib0145","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.yebeh.2010.01.016","article-title":"A prospective audit of adjunctive zonisamide in an everyday clinical setting","volume":"17","author":"Stephen","year":"2010","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2014.04.014_bib0150","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S1474-4422(08)70202-3","article-title":"Sudden unexpected death in epilepsy: current knowledge and future directions","volume":"7","author":"Tomson","year":"2008","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.eplepsyres.2014.04.014_bib0155","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.yebeh.2011.11.026","article-title":"Rational polytherapy with lacosamide in clinical practice: results of a Spanish cohort analysis RELACOVA","volume":"23","author":"Villanueva","year":"2012","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2014.04.014_bib0160","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.yebeh.2013.07.013","article-title":"Which drug-induced side effects would be tolerated in the prospect of seizure control?","volume":"29","author":"Witt","year":"2013","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2014.04.014_bib0165","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.seizure.2013.03.016","article-title":"Neurological adverse events of new generation sodium blocker antiepileptic drugs Meta-analysis of randomized, double-blinded studies with eslicarbazepine acetate, lacosamide and oxcarbazepine","volume":"22","author":"Zaccara","year":"2013","journal-title":"Seizure"}],"container-title":["Epilepsy Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121114001302?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121114001302?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:31:58Z","timestamp":1760275918000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920121114001302"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":33,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["S0920121114001302"],"URL":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2014.04.014","relation":{},"ISSN":["0920-1211"],"issn-type":[{"value":"0920-1211","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term safety and efficacy of eslicarbazepine acetate in patients with focal seizures: Results of the 1-year ESLIBASE retrospective study","name":"articletitle","label":"Article Title"},{"value":"Epilepsy Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2014.04.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}